WA
ABBV icon

Wealth Alliance’s AbbVie ABBV Stock Holding History

Wealth Alliance’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.38M Buy
21,367
+414
+2% +$89.1K 0.45% 44
2026
Q1 		$4.56M Sell
20,953
-986
-4% -$219K 0.45% 43
2025
Q4 		$5.01M Sell
21,939
-1,640
-7% -$374K 0.49% 35
2025
Q3 		$5.46M Sell
23,579
-2,659
-10% -$541K 0.56% 29
2025
Q2 		$4.87M Buy
26,238
+2,303
+10% +$428K 0.54% 31
2025
Q1 		$5.01M Buy
23,935
+1,263
+6% +$246K 0.61% 26
2024
Q4 		$4.03M Buy
22,672
+779
+4% +$143K 0.48% 31
2024
Q3 		$4.32M Buy
21,893
+76
+0.3% +$14.2K 0.52% 29
2024
Q2 		$3.74M Sell
21,817
-67
-0.3% -$11.1K 0.48% 32
2024
Q1 		$3.99M Sell
21,884
-3,847
-15% -$663K 0.52% 27
2023
Q4 		$3.99M Buy
25,731
+2,091
+9% +$305K 0.56% 28
2023
Q3 		$3.52M Buy
23,640
+908
+4% +$133K 0.56% 28
2023
Q2 		$3.06M Sell
22,732
-1,413
-6% -$207K 0.46% 35
2023
Q1 		$3.85M Sell
24,145
-435
-2% -$66.5K 0.62% 22
2022
Q4 		$3.97M Buy
24,580
+798
+3% +$122K 0.71% 18
2022
Q3 		$3.19M Sell
23,782
-551
-2% -$79.1K 0.63% 23
2022
Q2 		$3.73M Buy
24,333
+750
+3% +$115K 0.72% 23
2022
Q1 		$3.82M Buy
23,583
+1,181
+5% +$172K 0.78% 18
2021
Q4 		$3.03M Buy
22,402
+296
+1% +$35K 0.61% 26
2021
Q3 		$2.38M Buy
22,106
+578
+3% +$66K 0.54% 37
2021
Q2 		$2.42M Buy
21,528
+1,840
+9% +$207K 0.57% 35
2021
Q1 		$2.13M Buy
19,688
+592
+3% +$63.3K 0.6% 30
2020
Q4 		$2.05M Buy
19,096
+1,287
+7% +$124K 0.6% 31
2020
Q3 		$1.56M Buy
17,809
+68
+0.4% +$6.4K 0.56% 39
2020
Q2 		$1.74M Buy
17,741
+4,555
+35% +$401K 0.69% 29
2020
Q1 		$1M Buy
13,186
+2,018
+18% +$172K 0.54% 41
2019
Q4 		$989K Buy
+11,168
New +$927K 0.7% 39

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wealth Alliance's ABBV Position: Q2 2026 in Review

Wealth Alliance increased its AbbVie (ABBV) stake by 2% in Q2 2026, buying an estimated $89.1K and bringing the position to 21,367 shares worth $5.38M. The position accounts for 0.45% of the portfolio, ranked #44.

Wealth Alliance first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $5.46M in Q3 2025. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Wealth Alliance held 21,367 shares of AbbVie worth $5.38M as of Q2 2026.
  • Wealth Alliance bought 414 AbbVie shares in Q2 2026, an estimated $89.1K.
  • AbbVie made up 0.45% of Wealth Alliance's portfolio in Q2 2026, its #44 holding.
  • Wealth Alliance first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Wealth Alliance's AbbVie position peaked at $5.46M in Q3 2025.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wealth Alliance's 13F filing for Q2 2026, filed 11 Aug 2026.